Home » Stocks » MRK

Merck & Co., Inc. (MRK)

Stock Price: $74.45 USD 1.32 (1.81%)
Updated Mar 8, 2021 3:46 PM EST - Market open
Market Cap 185.04B
Revenue (ttm) 47.99B
Net Income (ttm) 7.07B
Shares Out 2.53B
EPS (ttm) 2.78
PE Ratio 26.78
Forward PE 11.00
Dividend $2.44
Dividend Yield 3.28%
Trading Day March 8
Last Price $74.45
Previous Close $73.13
Change ($) 1.32
Change (%) 1.81%
Day's Open 74.16
Day's Range 73.40 - 75.56
Day's Volume 12,023,396
52-Week Range 63.76 - 86.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 hours ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI...

Zacks Investment Research - 4 hours ago

Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptoma...

Reuters - 5 hours ago

U.S. President Biden will meet with the chief executives of Johnson & Johnson and Merck & Co Inc at the White House on Wednesday after the companies recently announced a COVID-19 vaccine manuf...

Other stocks mentioned: JNJ
Investors Business Daily - 5 hours ago

Merck stock popped Monday after its Ridgeback Biotherapeutics-partnered Covid-19 treatment showed promise in an interim analysis of a Phase 2 test. But Merck stock is still under pressure.

Benzinga - 9 hours ago

Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug a...

Zacks Investment Research - 2 days ago

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 days ago

MIAMI & KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupi...

Zacks Investment Research - 2 days ago

Merck (MRK) closed the most recent trading day at $73.13, moving +1.33% from the previous trading session.

GeekWire - 3 days ago

Vancouver, Wash.

Bloomberg Markets and Finance - 4 days ago

Demand for Covid Products to Remain High: Merck KGaA CEO

Mar.04 -- Merck KGaA Chief Executive Officer Stephan Oschmann says that while the Covid-19 vaccine rollout is “encouraging,” he expects the virus “will be endemic in future.” Oschmann spoke on...

Business Wire - 4 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Begins Tender Offer to Acquire Pandion Therapeutics

CNBC International TV - 4 days ago

We were cautious during the pandemic, but our businesses performed well: Merck KGaA CEO

Stefan Oschmann, CEO of Merck KGaA, discusses the company's full-year earnings.

PRNewsWire - 4 days ago

SAN JOSE, Calif., March 4, 2021 /PRNewswire/ -- Intermolecular, Inc. ("Intermolecular"), the trusted partner for materials innovation and a wholly-owned subsidiary of Merck KGaA, Darmstadt, Ge...

Reuters - 4 days ago

Germany's Merck KGaA predicted further earnings gains in 2021 as an effort by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its supplies for ...

CNBC Television - 5 days ago

Merck, Bristol Myers and Pfizer...which one is most attractive?

The "Halftime Report" traders answer viewer questions in #AskHalftime.

Other stocks mentioned: BMY, PFE
Zacks Investment Research - 5 days ago

Travel stocks will benefit from a return to normalcy

Other stocks mentioned: AAL, ABNB, AWAY, DAL, JETS, JNJ, LUV, TRIP, UAL
CNBC Television - 5 days ago

Cramer on Merck, J&J Covid vaccine manufacturing partnership

“What this means is that Americans are going to get shots in the arm faster, and we're very excited about the potential impact that this can have overall on the situation,” Johnson & Johnson C...

Other stocks mentioned: JNJ
Zacks Investment Research - 5 days ago

Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.

Other stocks mentioned: JNJ
Business Wire - 5 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021

Business Wire - 5 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Barclays Global Healthcare Conference

CNBC Television - 5 days ago

Johnson & Johnson CEO on working with Merck to produce 100 million vaccines by summer

"The real war here is against Covid-19 and I couldn't think of a better partner than Merck, a company with an incredibly strong reputation," Johnson & Johnson CEO Alex Gorsky said of his compa...

Other stocks mentioned: JNJ
CNBC - 5 days ago

Johnson & Johnson CEO Alex Gorsky discussed on Tuesday the company's unprecedented partnership with rival Merck to boost production of its Covid-19 vaccine.

Other stocks mentioned: JNJ
CNBC Television - 5 days ago

Merck's J&J partnership reminiscent of penicillin in 1942

CNBC's Meg Tirrell on the partnership between Merck and Johnson & Johnson partnership to manufactures J&J's Covid vaccine. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Se...

Other stocks mentioned: JNJ
Business Wire - 5 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck with Funding to Expand Merck's Manufacturing Capacity

New York Post - 6 days ago

Merck will help rival drugmaker Johnson & Johnson produce its single-dose coronavirus vaccine, the White House said Tuesday. The two pharmaceutical giants have reached a “historic manufacturin...

Other stocks mentioned: JNJ
Yahoo Finance - 6 days ago

Johnson and Johnson will get help from Merck to produce COVID-19 vaccines

#Johnson&Johnson #coronavirusvaccine #COVID19vaccine Dr. Andre Campbell, Professor of Surgery of UCSF & ICU Physician and Trauma Surgeon at Zuckerberg San Francisco General Hospital, joins Yah...

Other stocks mentioned: JNJ
Investors Business Daily - 6 days ago

Merck will reportedly step in to help Johnson & Johnson manufacture its coronavirus vaccine in a deal that binds two rival vaccine stocks. J&J is reportedly behind in production.

Other stocks mentioned: JNJ
Yahoo Finance - 6 days ago

Coronavirus vaccine: Merck will help produce Johnson & Johnson COVID-19 vaccine

#coronavirusvaccine #COVID19vaccine #coronavirus Harvard Medical School Professor Dr. Ali Raja discusses vaccine distribution with Yahoo Finance's Aikiko Fujita and Zack Guzman.

Other stocks mentioned: JNJ
Reuters - 6 days ago

The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki s...

Other stocks mentioned: JNJ
CNBC Television - 6 days ago

How Merck could assist J&J's covid vaccine manufacturing efforts

CNBC's Meg Tirrell reports that President Biden is set to announce later this afternoon that Merck will help make rival Johnson & Johnson's Covid vaccine.

Other stocks mentioned: JNJ
Reuters - 6 days ago

Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, a White House official said.

Other stocks mentioned: JNJ
CNBC Television - 6 days ago

Jim Cramer: Merck helping J&J with manufacturing is a sign 'we're going to beat this thing'

President Joe Biden will announce Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine, a senior administration official confirmed to NBC News. CNBC's Ji...

Other stocks mentioned: JNJ
CNBC Television - 6 days ago

Biden to announce Merck will aid in manufacturing of J&J Covid vaccine

President Joe Biden will announce Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine, a senior administration official confirmed to NBC News. CNBC's Be...

Other stocks mentioned: JNJ
Benzinga - 6 days ago

U.S. President Joe Biden will announce that Merck & Co (NYSE: MRK) will help manufacture its rival Johnson & Johnson's (NYSE: JNJ) newly authorized coronavirus vaccine to boost the supply, Was...

Other stocks mentioned: JNJ
CNBC - 6 days ago

Other stocks mentioned: JNJ
Business Wire - 6 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide

GeekWire - 6 days ago

New funds, new partners: Seattle's Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics.

Business Wire - 6 days ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pandion ...

Business Wire - 6 days ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US

Benzinga - 1 week ago

The FDA has accepted Merck & Co Inc's (NYSE: MRK) marketing application seeking approval for gefapixant, for review. The selective P2X3 receptor antagonist is being developed to treat refracto...

Reuters - 1 week ago

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.

Business Wire - 1 week ago

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review

PRNewsWire - 1 week ago

DARMSTADT, Germany, March 1, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a worldwide in-licensing agreement with Debiopharm, ...

GuruFocus - 1 week ago

Hillman Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: BK, JWN, KHC, MSFT, NKE, SPY
Benzinga - 1 week ago

Merck & Co Inc (NYSE: MRK) had reported a significant snag in its latest annual filing (10K), wherein the company has received feedback from the FDA regarding its COVID-19 drug, MK-7110. The a...

Investors Business Daily - 1 week ago

Is Merck stock a buy as the company plans to buy Pandion Therapeutics, an early-stage biotech testing drugs for autoimmune diseases? Check out Merck stock chart and materials.

The Motley Fool - 1 week ago

Here's how you can take advantage of the latest sell-off in a stalwart pharma stock.

The Motley Fool - 1 week ago

You'd vault into the air too if a big-name pharmaceutical paid a high premium for your stock.

Other stocks mentioned: PAND
GuruFocus - 1 week ago

Seeking to beef up a product line dominated by the cancer drug Keytruda, Merck & Co. Inc. (NYSE:MRK) has made another in a series of acquisitions. The Kenilworth, New Jersey-based drug giant i...

Business Wire - 1 week ago

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health Completes Acquisition of Poultry Sense Limited

About MRK

Merck & Company provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; ... [Read more...]

Industry
Drug Manufacturers-General
Founded
2000
CEO
Kenneth Frazier
Employees
73,000
Stock Exchange
NYSE
Ticker Symbol
MRK
Full Company Profile

Financial Performance

In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 96.33, which is an increase of 29.39% from the latest price.

Price Target
$96.33
(29.39% upside)
Analyst Consensus: Buy